Literature DB >> 579344

Bioavailability of three phenytoin preparations in healthy subjects and in epileptics.

B Rambeck, H E Boenigk, E Stenzel.   

Abstract

Serum phenytoin concentrations have been studied in epileptic patients and healthy subjects taking tablets of phenytoin calcium (Desitin), A, phenytoin acid (Desitin), B, and phenytoin acid (Nordmark), C. Retrospective data and prospective investigation of hospitalized patients on long-term phenytoin treatment showed that significantly higher serum concentrations of phenytoin were produced by the phenytoin acid preparations B and C than by the phenytoin calcium preparation A. In a cross over study six volunteers received 200 mg/day of preparations A, B, and C for three weeks. In this study, too, higher phenytoin serum concentrations were produced by B and C than by A, although the differences were not statistically significant. The reasons for the discrepancies between the studies in healthy and epileptic subjects are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 579344     DOI: 10.1007/bf00607428

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  [Biological availability--a comparison between 3 phenytoin preparations].

Authors:  G Alván; A Bertler; O Eeg-Olofsson; E Karlsson; F Sjöqvist; G Tomson
Journal:  Lakartidningen       Date:  1975-06-11

2.  Bioavailability of phenytoin. A comparison of two preparations.

Authors:  M J Stewart; B R Ballinger; E J Devlin; A Y Miller; A C Ramsay
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

3.  Bioavailability of phenytoin from various pharmaceutical preparations in children.

Authors:  J I Manson; S M Beal; A Magarey; A C Pollard; W J O'Reilly; L N Sansom
Journal:  Med J Aust       Date:  1975-10-11       Impact factor: 7.738

4.  Simplification of drug dosage calculation by application of the surface area principle.

Authors:  J D CRAWFORD; M E TERRY; G M ROURKE
Journal:  Pediatrics       Date:  1950-05       Impact factor: 7.124

5.  Clinical significance of generic inequivalence of three different pharmaceutical preparations of phenytoin.

Authors:  L Lund
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

6.  Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation.

Authors:  N Gerber; J G Wagner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-05

7.  Outbreak of anticonvulsant intoxication in an Australian city.

Authors:  J H Tyrer; M J Eadie; J M Sutherland; W D Hooper
Journal:  Br Med J       Date:  1970-10-31

8.  Letter: Bioavailability of phenytoin.

Authors:  P Tammisto; K Kauko; M Viukari
Journal:  Lancet       Date:  1976-01-31       Impact factor: 79.321

9.  Plasma level studies on different brands of sodium diphenylhydantoin (DPH) and primidone.

Authors:  S I Borst; C H Lockwood
Journal:  Int J Clin Pharmacol Biopharm       Date:  1975-10

10.  The elimination of phenytoin in man.

Authors:  M J Eadie; J H Tyrer; F Bochner; W D Hooper
Journal:  Clin Exp Pharmacol Physiol       Date:  1976 May-Jun       Impact factor: 2.557

View more
  6 in total

Review 1.  Is generic prescribing acceptable in epilepsy?

Authors:  F M Besag
Journal:  Drug Saf       Date:  2000-09       Impact factor: 5.606

2.  Effect of increased bioavailability of phenytoin tablets on serum phenytoin concentration in epileptic out-patients.

Authors:  P J Neuvonen; A Bardy; R Lehtovaara
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

3.  Comparison of serum phenytoin levels in epileptic patients who swallowed their phenytoin tablets with or without previous chewing.

Authors:  P Bielmann; T Levac
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

4.  Bioavailability and dissolution of proprietary and generic formulations of phenytoin.

Authors:  I Soryal; A Richens
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

5.  Impact of generic substitution of anticonvulsants on the treatment of epilepsy.

Authors:  A Richens
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

Review 6.  Clinical pharmacokinetics of phenytoin.

Authors:  A Richens
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.